| Ytd | 3.56% | |
| 1y | -32.03% |
| Open | 0.86 | Prev Close | 0.88 | Low | 0.86 | High | 0.89 | Mkt Cap | 32.67M |
| Vol | 48.64K | Avg Vol | 266.54K | EPS | -0.32 | P/E | -2.74 | Forward P/E | -3.10 |
| Beta | 0.99 | Short Ratio | 3.43 | Inst. Own | 8.18% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.89 | 200-d Avg | 0.95 | 1yr Est | 5.50 |
RNXT News
RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026
MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price tar
Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”)
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Conse
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer
RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnin
MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company
MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic T
Patent Expands Protection for the Company's RenovoCath Device, the Novel Dual-Occlusion Catheter-Bas
RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More RenovoRx Joins the Ranks of Go
RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase II
TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Ex
Company has the funding, business plan, leadership and infrastructure to propel achievement of upcom
MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company
Bolstered Cash Position Expected to Capitalize the Company's Momentum Towards Important Milestones,
Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Request
On Wednesday, 807 companies reached new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
On Friday, 431 companies hit new 52-week lows.